RT Journal Article
T1 Biomarkers of fungal infection: Expert opinion on the current situation.
A1 Bouza, E
A1 Almirante, B
A1 García Rodríguez, J
A1 Garnacho-Montero, J
A1 Salavert, M
A1 Muñoz, P
A1 Sanguinetti, M
K1 1-3ß-D-Glucan
K1 Anti-Mannan
K1 CAGTA
K1 Candidemia
K1 Critical Care
K1 Galactomannan
K1 Intensive Care
K1 Invasive candidiasis
K1 Invasive fungal infections
K1 Mannan
K1 T2Candida
K1 antifungal stewardship
K1 fungal biomarkers
K1 invasive aspergillosis
AB The introduction of non-culture-based diagnostic techniques is revolutionizing the world of microbiological diagnosis and infection assessment. Fungi are no exception, and the introduction of biomarkers has opened up enormous expectations for better management of these entities. Biomarkers are diverse, their targets are also diverse and their evaluation has been done preferably in an individualized use and with deficient designs. Less is known about the value of the combined use of biomarkers and the impact of the negativity of two or more biomarkers on antifungal treatment decisions has been poorly studied. Given the paucity of prospective, randomized and definitive studies, we have convened experts from different fields, with an interest in invasive fungal infections, to answer some questions about the current relevant use of fungal biomarkers. This document summarizes the answers of these experts to the different questions.
YR 2019
FD 2019-11-14
LK http://hdl.handle.net/10668/14692
UL http://hdl.handle.net/10668/14692
LA en
DS RISalud
RD May 9, 2025